A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Condition(s):Acute Myeloid LeukemiaLast Updated:March 12, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Acute Myeloid LeukemiaLast Updated:March 12, 2024Active, not recruiting
Condition(s):Insulin ResistanceLast Updated:November 7, 2023Completed
Condition(s):Advanced Malignant Neoplasm; Dermatologic ComplicationLast Updated:January 9, 2020Completed
Condition(s):Recurrent Acute Myeloid Leukemia; Recurrent Juvenile Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic SyndromeLast Updated:February 8, 2024Not yet recruiting
Condition(s):Lymphoblastic Leukemia, Acute, Childhood; Lymphoblastic Lymphoma; Peripheral T-cell LymphomaLast Updated:July 27, 2023Completed
Condition(s):Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic LeukemiaLast Updated:March 19, 2024Not yet recruiting
Condition(s):B Acute Lymphoblastic LeukemiaLast Updated:March 5, 2024Not yet recruiting
Condition(s):Sepsis; Septic ShockLast Updated:October 19, 2020Completed
Condition(s):PsoriasisLast Updated:October 16, 2019Unknown status
Condition(s):Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous LineageLast Updated:December 5, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.